Newsroom | 4462 results

INDIANAPOLIS--(BUSINESS WIRE)--Governor Braun visited Ossium Health's production facility, celebrating how the company embodies Indiana's reputation as a life sciences powerhouse....

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the Company will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. 25th Annual Needham Virtual Healthcare Conference Format: Virtual Corporate presentation Date/Time: Tuesday, April 14, 2026 at 9:30am...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced that the first patients have been dosed in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has the potential to be the first...

NEW YORK--(BUSINESS WIRE)--Polyphron and Cellino Show Tissue Manufacturing Works Across Any Patient Background...

COLUMBUS, Ohio--(BUSINESS WIRE)--Armatus has published data in Molecular Therapy Nucleic Acids describing TVR110, a first-in-class vectorized microRNA for CMT1A....

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

SAN DIEGO--(BUSINESS WIRE)--Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics to improve the safety and efficacy of cancer therapies, today announced upcoming oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 and the Antibody Engineering & Therapeutics (AET) Europe conference. Voro Therapeutics will present new preclinical data showcasing the power of its proprietary PrimeBody biologics platform and the broad therapeu...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome FFPE kits that are now shipping to customers. This new solution is a breakthrough that enables true whole transcriptome single cell RNA sequencing from formalin-fixed, paraffin-embedded samples. Beginning today, cancer, neuroscience, and translational researchers can access...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs). Building on the eProtein Discovery™ membrane protein workflow capabilities1, the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of challenging therapeut...

SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, today announced it has entered an international collaboration with Rosebud Biosciences (“Rosebud”), Kantify, and Incite to evaluate off-target chemotherapeutic toxicities in patient-specific organoids. Building on iXCells’ recent partnership with Rosebud1 and funded by Incite, the project will initially focus on predicting toxicity in heart, liver, and kidn...